These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25947949)

  • 1. Educating Pharmacists on a Prescription Drug Monitoring Program.
    Fleming ML; Phan Y; Ferries EA; Hatfield MD
    J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
    J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the theory of planned behavior to examine pharmacists' intention to utilize a prescription drug monitoring program database.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels S; Novak S
    Res Social Adm Pharm; 2014; 10(2):285-96. PubMed ID: 23816495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances.
    Fass JA; Hardigan PC
    J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoting consistent use of prescription drug monitoring programs (PDMP) in outpatient pharmacies: Removing administrative barriers and increasing awareness of Rx drug abuse.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(3):509-14. PubMed ID: 26329535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of psychosocial predictors of Virginia pharmacists' intention to utilize a prescription drug monitoring program using the theory of planned behavior.
    Gavaza P; Fleming M; Barner JC
    Res Social Adm Pharm; 2014; 10(2):448-58. PubMed ID: 23953982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
    Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
    Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
    Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
    J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Florida physicians' knowledge and attitudes toward accessing the state prescription drug monitoring program as a prescribing tool.
    Gershman JA; Gershman JA; Fass AD; Popovici I
    Pain Med; 2014 Dec; 15(12):2013-9. PubMed ID: 24931295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
    Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
    Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
    Picco L; Lam T; Xia T; Nielsen S
    Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of pharmacists' likelihood to query prescription drug monitoring program databases.
    Arnold A; Bentley JP; Patel A; Holmes E
    J Am Pharm Assoc (2003); 2021; 61(5):614-622.e3. PubMed ID: 33994328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription Drug Monitoring Program: Registration and Use by Prescribers and Pharmacists Before and After Legal Mandatory Registration, California, 2010-2017.
    Shev AB; Wintemute GJ; Cerdá M; Crawford A; Stewart SL; Henry SG
    Am J Public Health; 2018 Dec; 108(12):1669-1674. PubMed ID: 30359105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances.
    Fendrich M; Bryan JK; Hooyer K
    Subst Use Misuse; 2018 Jul; 53(8):1324-1330. PubMed ID: 29297725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the theory of planned behavior to investigate community pharmacists' beliefs regarding engaging patients about prescription drug misuse.
    Fleming ML; Bapat SS; Varisco TJ
    Res Social Adm Pharm; 2019 Aug; 15(8):992-999. PubMed ID: 30442574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacists' perceptions regarding the impact of hydrocodone rescheduling on prescription volume, workflow management, and patient outcomes.
    Varisco TJ; Ogunsanya ME; Barner JC; Fleming ML
    J Am Pharm Assoc (2003); 2017; 57(2S):S51-S62. PubMed ID: 28292504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost.
    Upton C; Gernant SA; Rickles NM
    J Am Pharm Assoc (2003); 2020; 60(6):943-950. PubMed ID: 32792293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.